Achieve Life Sciences ACHV Payments to Acquire Marketable Securities

Payments to Acquire Marketable Securities at other companies

EyePoint, Inc. EYPT

$63.01M-36.7%

NVE CorporationNVEC

$13.06M+29.1%

UMH

UMH PropertiesUMH

$7K0.0%

TRV

Trevi Therapeutics, Inc.TRVI

$8.49M-69.2%

AbCellera Biologics Inc.ABCL

$166.31M+0.8%

DJT

Trump Media & Technology GroupDJT

$1.93M—

Other financials

Income statement

See full

Net income-$10.2M+20.7%

EPS (diluted)-$0.19+48.6%

Balance sheet

See full

Cash & equivalents$28.1M+116%

Total debt$5.6M+332%

Total equity$10.7M+3.9%

Total assets$33.1M+21.0%

Cash flow

See full

Operating cash flow-$6.9M+37.5%

CapEx$750.0—

Free cash flow-$12.4M—

Valuation

See full

Market cap$585.16M+404%

Enterprise value$562.71M+439%

Returns & leverage

See full

Return on equity-496.1%-906pp

Debt / equity0.5×+0.4×

Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireMarketableSecurities.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's payments to acquire marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Achieve Life Sciences's payments to acquire marketable securities?: Achieve Life Sciences (ACHV) reported payments to acquire marketable securities of $1.16M in Q1 2026.
How has Achieve Life Sciences's payments to acquire marketable securities changed year-over-year?: Achieve Life Sciences's payments to acquire marketable securities decreased by 65.6% year-over-year, from $3.36M to $1.16M.